Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiotepa-Containing Conditioning Regimen for Allo-HSCT in CMML
NCT07588594Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of thiotepa in chronic myelomonocytic leukemia (CMML), sponsored by Peking University People's Hospital. Primary endpoint: Relapse-Free Survival at 12 months. Started Feb 2026; status: recruiting.
02
Drugs
thiotepa
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT07588594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588594.